<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type='text/xsl' href='../../ld2webpage.xsl'?>
<LOBBYINGDISCLOSURE2>
  <imported>Y</imported>
  <pages>4</pages>
  <submitURL>
  </submitURL>
  <organizationName>NATIONAL PSORIASIS FOUNDATION</organizationName>
  <prefix>
  </prefix>
  <firstName>
  </firstName>
  <lastName>
  </lastName>
  <registrantDifferentAddress>N</registrantDifferentAddress>
  <address1>6600 SW 92ND AVENUE, SUITE 300</address1>
  <address2>
  </address2>
  <city>PORTLAND</city>
  <state>OR</state>
  <zip>97223</zip>
  <zipext>7195</zipext>
  <country>USA</country>
  <principal_city>Alexandria</principal_city>
  <principal_state>VA</principal_state>
  <principal_zip>22306</principal_zip>
  <principal_zipext>
  </principal_zipext>
  <principal_country>USA</principal_country>
  <contactIntlPhone>
  </contactIntlPhone>
  <selfSelect>Y</selfSelect>
  <clientName>NATIONAL PSORIASIS FOUNDATION</clientName>
  <clientGovtEntity>N</clientGovtEntity>
  <senateID>314658-12</senateID>
  <houseID>393810000</houseID>
  <reportYear>2016</reportYear>
  <reportType>Q1</reportType>
  <terminationDate>
  </terminationDate>
  <noLobbying>
  </noLobbying>
  <income>
  </income>
  <expenses>83000.00</expenses>
  <expensesMethod>B</expensesMethod>
  <printedName>Quardricos Driskell</printedName>
  <signedDate>5/13/2016 2:48:52 PM</signedDate>
  <alis>
    <ali_info>
      <issueAreaCode>BUD</issueAreaCode>
      <specific_issues>
        <description>FY16 Appropriations for Psoriatic Disease

Allocate $1.2 million in the Fiscal Year (FY) 2015 Labor, Health and Human Services, Education and Related Agencies (LHHS) Appropriations bill to implement a public health agenda for psoriasis and psoriatic arthritis at the Centers for Disease Control and Prevention (CDC). With this funding, the CDCs National Center for Health Statistics (NCHS) could begin implementation of the first ever psoriasis and psoriatic arthritis public health agenda by developing survey instruments, which will:

Increase the understanding of psoriasis, including the prevalence of the diseases and how age, sex, race, and ethnicity affect the course and burden of psoriasis;

Study how differences in genetic and nongenetic factors, such as environmental exposure and lifestyle,contribute to the occurrence and severity of psoriasis and psoriatic arthritis;

Examine the relationship of psoriasis to other serious diseases and develop public health strategies to reduce the burden of diseases and prevent the onset of comorbid conditions; and

Gain insight into the long term impact of psoriasis and psoriatic arthritis.</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control &amp; Prevention (CDC)</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Leah </lobbyistFirstName>
          <lobbyistLastName>Howard</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Quardricos</lobbyistFirstName>
          <lobbyistLastName>Driskell</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
    <ali_info>
      <issueAreaCode>HCR</issueAreaCode>
      <specific_issues>
        <description>1. Urge Congress to support efforts that increase access to care for people with psoriasis and psoriasis arthritis by supporting H.R.1600: Patients' Access to Treatments Act of 2015.  This bill limits copayments, coinsurance, and other cost sharing and out-of-pocket expenses for so called specialty tier drugs. This bill will help ensure that people with psoriasis and other chronic conditions have access to the therapy that their health care provider determines is most appropriate for them.

2. Support efforts to facilitate research efforts on psoriasis and psoriatic arthritis within institutes at the NIH. 


3. Worked with CDC's Chronic Disease Prevention and Health Promotion on initiative that will develop public health self-management interventions for persons with psoriatic disease and advance knowledge of the links between psoriatic disease and other chronic conditions

4. Urge Congress to support HR 2624/S.1488 Medicare Part D Beneficiary Appeals Fairness Act. Allows a Medicare part D eligible individual enrolled in the plan to request an exception to the tiered cost-sharing structure</description>
      </specific_issues>
      <federal_agencies>U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Centers For Disease Control &amp; Prevention (CDC)</federal_agencies>
      <lobbyists>
        <lobbyist>
          <lobbyistFirstName>Leah</lobbyistFirstName>
          <lobbyistLastName>Howard</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>Quardricos</lobbyistFirstName>
          <lobbyistLastName>Driskell</lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
        <lobbyist>
          <lobbyistFirstName>
          </lobbyistFirstName>
          <lobbyistLastName>
          </lobbyistLastName>
          <lobbyistSuffix>
          </lobbyistSuffix>
          <coveredPosition>
          </coveredPosition>
          <lobbyistNew>N</lobbyistNew>
        </lobbyist>
      </lobbyists>
      <foreign_entity_issues>
      </foreign_entity_issues>
    </ali_info>
  </alis>
  <updates>
    <clientAddress>
    </clientAddress>
    <clientCity>
    </clientCity>
    <clientState>
    </clientState>
    <clientZip>
    </clientZip>
    <clientZipext>
    </clientZipext>
    <clientCountry>
    </clientCountry>
    <prinClientCity>
    </prinClientCity>
    <prinClientState>
    </prinClientState>
    <prinClientZip>
    </prinClientZip>
    <prinClientZipext>
    </prinClientZipext>
    <prinClientCountry>
    </prinClientCountry>
    <generalDescription>
    </generalDescription>
    <inactive_lobbyists>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
      <inactive_lobbyist>
        <firstName>
        </firstName>
        <lastName>
        </lastName>
        <suffix>
        </suffix>
      </inactive_lobbyist>
    </inactive_lobbyists>
    <inactive_ALIs>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
      <ali_Code>
      </ali_Code>
    </inactive_ALIs>
    <affiliatedUrl>
    </affiliatedUrl>
    <affiliatedOrgs>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
      <affiliatedOrg>
        <affiliatedOrgName>
        </affiliatedOrgName>
        <affiliatedOrgAddress>
        </affiliatedOrgAddress>
        <affiliatedOrgCity>
        </affiliatedOrgCity>
        <affiliatedOrgState>
        </affiliatedOrgState>
        <affiliatedOrgZip>
        </affiliatedOrgZip>
        <affiliatedOrgCountry>
        </affiliatedOrgCountry>
        <affiliatedPrinOrgCity>
        </affiliatedPrinOrgCity>
        <affiliatedPrinOrgState>
        </affiliatedPrinOrgState>
        <affiliatedPrinOrgCountry>
        </affiliatedPrinOrgCountry>
      </affiliatedOrg>
    </affiliatedOrgs>
    <inactiveOrgs>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
      <inactiveOrgName>
      </inactiveOrgName>
    </inactiveOrgs>
    <foreignEntities>
      <foreignEntity>
        <name>
        </name>
        <address>
        </address>
        <city>
        </city>
        <state>
        </state>
        <country>
        </country>
        <prinCity>
        </prinCity>
        <prinState>
        </prinState>
        <prinCountry>
        </prinCountry>
        <contribution>
        </contribution>
        <ownership_Percentage>
        </ownership_Percentage>
      </foreignEntity>
    </foreignEntities>
    <inactive_ForeignEntities>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
      <inactive_ForeignEntity>
      </inactive_ForeignEntity>
    </inactive_ForeignEntities>
  </updates>
</LOBBYINGDISCLOSURE2>